TY - JOUR ID - TI - Assessment of cytogenetic response after treatment with imatinib mesylate in patients with chronic phase chronic myeloid leukemia AU - Alaa Fadhil Alwan PY - 2014 VL - 3 IS - 1 SP - 56 EP - 61 JO - Iraq Joural of Hematology المجلة العراقية لامراض الدم SN - 20728069 25432702 AB - Background: Chronic myeloid leukemia (CML) is a myeloproliferative disorder affecting hematopoietic stem cells andaffects predominantly granulocyte progenitor line. It is characterized by acquired chromosomal abnormality which calledthe Philadelphia chromosome (Ph+) in 95% of cases. Imatinib mesylate is a powerful and selective competitive inhibitorof BCR-ABL tyrosine kinase. Imatinib mesylate is the first molecular target therapy for the treatment of CMLObjectives: The aim of this study was to evaluate the cytogenetic response in 58 patients with CML in chronic phasetreated with imatinib mesylate.Materials and methods: A prospective study conducted at the national center of hematology /Almustansiriya University,Baghdad, Iraq from April 2011 to December 2013, fifty-eight patients with CML in chronic phase (32 male and 26female) were enrolled in this study. All patients were carrying the BCR-ABL fusion gene and treated with Imatinibmesylate (Glivic® Novartis) at 400 mg daily for at least 12 monthsResults: There were 32 male and 26 female with male to female ratio (1.1:1).the median age was 36 year (range 14-64years). The median duration of treatment with imatinib was 18 months (range 12 to 32 months). Complete hematologicresponses (CHR) were attained in 54 of 58 (93%) patients treated during the first 3 months of imatinib therapy, where 11(19%) of patients reached CHR after 1 month, 35 (60%) got CHR within 2 months of treatment with imatinib.Cytogenetic response rates to imatinib therapy at 6 and 12months. : Major cytogenetic response achieved in 35 (70%), 48(92.3%) patients and minor cytogenetic response attained in 15 (30%), 4 (7.7%) patient at 6, 12 month respectively.Imatinib was usually safe and well tolerated. The vast majority of adverse effects were grade 1 and 2 and bone pain wasthe most common (86.2%).Conclusion: After a median follow-up of 18 months, this study confirm that imatinib therapy induced induce durableand sustained hematological and cytogenetic responses in a high proportion of patients with chronic-phase CML. theresponse rates of imatinib therapy were similar to those reported in other countries. Imatinib was safe and well-toleratedwith manageable side effects.

ER -